Advertisement

Acta Neurologica Belgica

, Volume 118, Issue 2, pp 331–333 | Cite as

Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab

  • Souraya El SankariEmail author
  • Géraldine Dahlqvist
  • Laurent Monino
  • Vincent van Pesch
Letter to the Editor

Sir,

In two large phase III clinical studies with relapsing–remitting multiple sclerosis (RR-MS) patients, alemtuzumab (ATZ) has demonstrated high efficacy on the risk of relapse, sustained accumulation of disability, and MRI endpoints [1]. Among the side effects of ATZ, secondary organ-specific autoimmunity has been described, mainly directed towards the thyroid. We report the first case of an early autoimmune hepatitis (AIH) occurring in a MS patient after completion of two treatment cycles with ATZ.

A 25-year-old female patient was diagnosed with RR-MS in September 2011. She declined a first-line treatment proposal. During the subsequent year, she presented with four relapses and was started on monthly infusions of natalizumab in December 2012. This treatment was interrupted after 22 infusions due to JC virus seroconversion and fear of progressive multifocal leukoencephalopathy. The patient received two courses of ATZ in November 2014 and 2015 successively. She remained stable with...

Notes

Funding

This study has received no funding.

Compliance with ethical standards

Conflict of interest

Souraya ElSankari has received travel grants from Biogen, Bayer Schering, Sanofi Genzyme, Merck, and Teva. Her institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Sanofi Genzyme, Merck, as well as research grants from Novartis Pharma, Roche and Bayer Schering. Géraldine Dahlqvist: reports no disclosures. Laurent Monino: reports no disclosures. Vincent van Pesch: has received travel grants from Biogen, Bayer Schering, Sanofi Genzyme, Merck, Teva, Novartis Pharma and Roche. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Sanofi Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma, Roche and Bayer Schering.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendements.

Informed consent

Informed consent was obtained from the subject included in the study.

References

  1. 1.
    Coles AJ, Cohen JA, Fox EJ et al (2017) Alemtuzumab CARE-MS II 5 years follow-up: efficacy and safety findings. Neurology 89:1117–1126CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L (2015) Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol 27:1175–1179CrossRefPubMedGoogle Scholar
  3. 3.
    De Seze J, Canva Delcambre V, Fajardy I et al (2005) Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler 11:691–693CrossRefPubMedGoogle Scholar
  4. 4.
    Cação G, Santos E, Martins Silva A (2018) Concurrent autoimmune hepatitis in multiple sclerosis. Mult Scler 24(3):350–353CrossRefPubMedGoogle Scholar
  5. 5.
    Hennes EM, Zeniya M, Czaja AJ et al (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169–176CrossRefPubMedGoogle Scholar
  6. 6.
    Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K (2017) Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 74(8):961–969CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Belgian Neurological Society 2018

Authors and Affiliations

  1. 1.Department of NeurologyCliniques Universitaires Saint-LucBrusselsBelgium
  2. 2.Department of Hepato-GastroEnterologyCliniques Universitaires Saint-LucBrusselsBelgium

Personalised recommendations